NetworkNewsBreaks Archive - Page 408 of 2094

ThursdayJan 25, 2024 2:39 pm

NetworkNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Announces Results of Special Meeting

Renovaro BioSciences (NASDAQ: RENB), a biotechnology corporation focusing on cell, gene and immunotherapy, has announced the results of its special meeting of shareholders (“special meeting”) held at 12:00 p.m. ET on Jan. 25, 2024. According to the announcement, all matters put forward before the company’s shareholders for consideration and approval, as set out in Renovaro’s definitive proxy statement dated Jan. 3, 2024, were approved by the requisite number of votes cast at the meeting. For complete results on all matters voted on at the special meeting, review the company’s Form 8-K, which will be filed on EDGAR. To view the full…

ThursdayJan 25, 2024 2:07 pm

NetworkNewsBreaks — Boston Hemp Inc. Unveils New Product Designed to Redefine Cannabis Consumption

Boston Hemp, a pioneer in the cannabis industry, has launched its latest product: THCa Crumble Extract. According to the announcement, the groundbreaking new product showcases the company's commitment to providing consumers with high-quality, cutting-edge solutions for a diverse range of cannabis experiences. A carefully crafted concentrate, THCa Crumble Extract is designed to “harness” the power of tetrahydrocannabinolic acid (“THCa”) and provides the user with a full-spectrum, entourage effect during a premium, authentic cannabis encounter. THCa Crumble offers purity and potency as well as versatility, allowing users to explore various methods of consumption, including dabbing, vaporizing or incorporating the substance into…

ThursdayJan 25, 2024 1:56 pm

NetworkNewsBreaks – ARway.ai (CSE: ARWY) (OTC: ARWYF) (FSE: E65) Announces Participation at Upcoming RainFocus INSIGHT Event

ARway.ai (CSE: ARWY) (OTC: ARWYF) (FSE: E65), an artificial intelligence (“AI”)-powered augmented-reality experience platform with a disruptive no-code, no-beacon spatial computing solution enabled by visual marker tracking with centimeter precision, will be presenting at next week’s RainFocus INSIGHT conference. The event is slated for Jan. 30–Feb. 1, 2024, in Salt Lake City. During the premier event, which is designed for leaders in events, marketing and technology, ARway.ai CEO Evan Gappelberg will present on the main stage during the conference’s “Pitch Tank” segment, which is slated for Jan. 30. During his presentation, Gappelberg will provide insights into ARway.ai's cutting-edge spatial computing…

ThursdayJan 25, 2024 1:49 pm

NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Scientific Research Collaborator Receives Prestigious Louis-Jeantet Prize

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, is congratulating its colead scientific research collaborator Professor Dr. Dirk Görlich, who is this year’s Louis-Jeantet Prize recipient. A director at the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”), Görlich and his colleague Dr. Matthias Dobbelstein, from the University Medical Center Göttingen (“UMG”), lead teams that have collaborated with Scinai in the discovery of nanosized VHH antibodies (NanoAbs). These NanoAbs form the basis of Scinai's innovative, derisked pipeline. In announcing the award, MPI-NAT noted that Görlich received the recognition for "discovering a new kind of biological matter that…

ThursdayJan 25, 2024 1:14 pm

NetworkNewsBreaks – D-Wave Announces 1,200+ Qubit Advantage2(TM) Prototype, Strategic Collaboration with Deloitte Canada

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services and the world’s first commercial supplier of quantum computers, today announced it has calibrated a 1,200+ qubit Advantage2(TM) prototype, which will soon be available in the company’s Leap(TM) real-time quantum cloud service. Developed with a lower-noise, multilayer superconducting integrated-circuit fabrication stack, the new prototype demonstrates significant performance gains on hard optimization problems and is expected to be particularly powerful for new use cases such as machine learning. “The new Advantage2 prototype represents a giant step up in performance,” said Mark W. Johnson, senior vice president…

ThursdayJan 25, 2024 12:48 pm

NetworkNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) to Participate at Lytham Partners 2024 Investor Select Conference, Signs Fourth Behavioral Health Provider

SOBR Safe (NASDAQ: SOBR) (“SOBRsafe(TM)”), a provider of next-generation transdermal alcohol detection solutions, has announced that its CEO Dave Gandini will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference. The event is taking place virtually on Feb. 1, 2024, with the fireside chat slated to begin at 11:00 a.m. ET. Interested parties should visit https://ibn.fm/zCmjF or the company’s website to access the webcast, which will also be available for replay following the event. In addition, the company today announced that it has signed its fourth behavioral health provider, based…

ThursdayJan 25, 2024 10:45 am

NetworkNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Names New CFO, Board Member

Freight Technologies (NASDAQ: FRGT), has announced key changes to its executive team and board of directors. Freight Technologies is a technology company whose custom-developed Fr8App, an industry-leading, freight-matching platform powered by AI and machine-learning and offers a real-time portal for business-to-business (“B2B”) cross-border shipping and domestic shipping within the USMCA region. The company appointed Don Quinby as its new chief financial officer while announcing that Paul Freudenthaler, the company’s former CFO, was named a member of FRGT’s board of directors; the changes were effective Jan. 19, 2024. According to the announcement, the changes support Fr8Tech's commitment to promoting internal talent…

ThursdayJan 25, 2024 10:12 am

NetworkNewsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) Received Official Notice from NASDAQ, Regains Compliance with Minimum Bid Price Requirement

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has regained compliance with NASDAQ’s minimum-bid price requirement. The company has officially received notice of the status change from the NASDAQ Stock Market LLC. The notice confirmed that Mullen regained compliance with NASDAQ Listing Rule 5550(a)(2) and will continue to be listed and traded on the NASDAQ Capital Market. The announcement also noted that the NASDAQ Hearings Panel has given the company until March 8, 2024, to demonstrate compliance with NASDAQ Listing Rule 5620(a), which is the annual shareholder meeting requirement. Mullen has scheduled its Annual Meeting of Stockholders for…

WednesdayJan 24, 2024 3:45 pm

NetworkNewsBreaks – Correlate Energy Corp. (CIPI) Providing Clients with Best-in-Class Sustainability Solutions

Correlate (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform for distributed energy solutions across North America, recently completed solar projects for American Tire Distributors’ headquarters and Continental Envelope’s manufacturing plant and announced it had commenced a third project in Reading, Pennsylvania. “The first project was completed at American Tire Distributors (‘ATD’) headquarters in Huntersville, North Carolina. The initiative aims to reduce ATD’s carbon footprint and generate substantial cost savings by reducing reliance on traditional energy sources. Over the next two decades, it’s expected to reduce CO2 emissions by 5,463 tons… The second solar project was constructed at Continental Envelope’s…

WednesdayJan 24, 2024 3:15 pm

NetworkNewsBreaks – Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics (OTCQB: SIGY) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, which is the leading cause of hospital deaths in the United States... In vitro studies have demonstrated the ability of Sigyn Therapy to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma… Sigyn designed the ImmunePrep platform to leverage the use of therapeutic antibodies…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks